Conference Coverage

VIDEO: New MS ambulatory measure could fill clinical gap


 

REPORTING FROM ACTRIMS FORUM 2018

SAN DIEGO – Although clinical tools to assess ambulatory function among people with multiple sclerosis exist, some measure it as part of a comprehensive assessment while others require the patient to answer many questions and then clinicians to calculate a score.

To devise a more targeted, simpler instrument, Emily Evans, MD, and her colleagues developed the PDAS or Patient Derived Ambulation Scale. They evaluated the correlation of this single-item scale to assess ambulation – an important measure of patient function – and evaluated how the results correlated with existing tools such as the Patient Determined Disease Steps and 12-item MS Walking Scale. Dr. Evans presented preliminary findings at the ACTRIMS Forum 2018, held by the Americas Committee for Treatment and Research in Multiple Sclerosis.

“We feel this is a quick test that can be readily implemented into clinical practice,” Dr. Evans, a neurologist at the John L. Trotter MS Center at Washington University in St. Louis, said in a video interview.

Recommended Reading

Study sheds light on pregnancy outcomes following ocrelizumab treatment
MDedge Internal Medicine
Pregnancy and MS: How do they affect each other?
MDedge Internal Medicine
Preliminary results promising from ublituximab phase II study for MS
MDedge Internal Medicine
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
MDedge Internal Medicine
FDA: Gadolinium retention prompts new GBCA class warning, safety measures
MDedge Internal Medicine
FDA cites manufacturer of autologous stem cells for regulatory, manufacturing missteps
MDedge Internal Medicine
Two MS diagnostic criteria found to have similar accuracy
MDedge Internal Medicine
Rituximab may outperform some other first-line multiple sclerosis treatments
MDedge Internal Medicine
2017 update to McDonald criteria loosens MS diagnosis somewhat
MDedge Internal Medicine
VIDEO: Alemtuzumab associated with long-term MS control in TOPAZ study
MDedge Internal Medicine